Cargando…

Renal Disturbances during and after Radioligand Therapy of Neuroendocrine Tumors—Extended Analysis of Potential Acute and Chronic Complications

Neuroendocrine tumors (NEN) are a group of neoplasms that arise from hormonal and neural cells. Despite a common origin, their clinical symptoms and outcomes are varied. They are most commonly localized in the gastrointestinal tract. Targeted radioligand therapy (RLT) is a treatment option which has...

Descripción completa

Detalles Bibliográficos
Autores principales: Saracyn, Marek, Durma, Adam Daniel, Bober, Barbara, Lubas, Arkadiusz, Kołodziej, Maciej, Kapusta, Waldemar, Dmochowska, Beata, Kamiński, Grzegorz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138694/
https://www.ncbi.nlm.nih.gov/pubmed/37108668
http://dx.doi.org/10.3390/ijms24087508
_version_ 1785032768108888064
author Saracyn, Marek
Durma, Adam Daniel
Bober, Barbara
Lubas, Arkadiusz
Kołodziej, Maciej
Kapusta, Waldemar
Dmochowska, Beata
Kamiński, Grzegorz
author_facet Saracyn, Marek
Durma, Adam Daniel
Bober, Barbara
Lubas, Arkadiusz
Kołodziej, Maciej
Kapusta, Waldemar
Dmochowska, Beata
Kamiński, Grzegorz
author_sort Saracyn, Marek
collection PubMed
description Neuroendocrine tumors (NEN) are a group of neoplasms that arise from hormonal and neural cells. Despite a common origin, their clinical symptoms and outcomes are varied. They are most commonly localized in the gastrointestinal tract. Targeted radioligand therapy (RLT) is a treatment option which has proven to be successful in recent studies. However, the possible outcomes and true safety profile of the treatment need to be fully determined, especially by new, more sensitive methods. Our study aimed to present an extended analysis of acute and chronic renal complications during and after radioligand therapy using, for the first time in the literature, innovative and complex renal parameters. Forty patients with neuroendocrine tumors underwent four courses of radioligand therapy with [(177)Lu]Lu-DOTATATE or [(177)Lu]Lu/[(90)Y]Y-DOTATATE. Radioisotopes were administrated in intervals of 8–12 weeks, with concurrent intravenous nephroprotection. New detailed and sensitive renal parameters were used to determine the renal safety profile during and after radioisotope therapy for standard treatment of NEN. During the first and fourth courses of RLT, no change in the glomerular filtration rate (GFR) was observed. However, long-term observations one year after the treatment showed a 10% reduction in the GFR. During the first course of treatment, the fractional urea and calcium excretions increased, while the fractional potassium concentration decreased. The fractional calcium excretion remained highly increased in long-term observations. Decreases in urine IL-18, KIM-1 and albumin concentrations were observed during RLT. The concentrations of IL-18 and KIM-1 remained low even a year after therapy. The ultrasound parameters of renal perfusion changed during treatment, before partially returning to the baseline one year after therapy, and were correlated with the biochemical parameters of renal function. A permanent increase in diastolic blood pressure was correlated with the decrease in the GFR observed during the study. In this innovative and complex renal assessment during and after RLT, we found a permanent 10% per year decrease in the GFR and noticeable disturbances in renal tubule function. The diastolic blood pressure also increased.
format Online
Article
Text
id pubmed-10138694
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101386942023-04-28 Renal Disturbances during and after Radioligand Therapy of Neuroendocrine Tumors—Extended Analysis of Potential Acute and Chronic Complications Saracyn, Marek Durma, Adam Daniel Bober, Barbara Lubas, Arkadiusz Kołodziej, Maciej Kapusta, Waldemar Dmochowska, Beata Kamiński, Grzegorz Int J Mol Sci Article Neuroendocrine tumors (NEN) are a group of neoplasms that arise from hormonal and neural cells. Despite a common origin, their clinical symptoms and outcomes are varied. They are most commonly localized in the gastrointestinal tract. Targeted radioligand therapy (RLT) is a treatment option which has proven to be successful in recent studies. However, the possible outcomes and true safety profile of the treatment need to be fully determined, especially by new, more sensitive methods. Our study aimed to present an extended analysis of acute and chronic renal complications during and after radioligand therapy using, for the first time in the literature, innovative and complex renal parameters. Forty patients with neuroendocrine tumors underwent four courses of radioligand therapy with [(177)Lu]Lu-DOTATATE or [(177)Lu]Lu/[(90)Y]Y-DOTATATE. Radioisotopes were administrated in intervals of 8–12 weeks, with concurrent intravenous nephroprotection. New detailed and sensitive renal parameters were used to determine the renal safety profile during and after radioisotope therapy for standard treatment of NEN. During the first and fourth courses of RLT, no change in the glomerular filtration rate (GFR) was observed. However, long-term observations one year after the treatment showed a 10% reduction in the GFR. During the first course of treatment, the fractional urea and calcium excretions increased, while the fractional potassium concentration decreased. The fractional calcium excretion remained highly increased in long-term observations. Decreases in urine IL-18, KIM-1 and albumin concentrations were observed during RLT. The concentrations of IL-18 and KIM-1 remained low even a year after therapy. The ultrasound parameters of renal perfusion changed during treatment, before partially returning to the baseline one year after therapy, and were correlated with the biochemical parameters of renal function. A permanent increase in diastolic blood pressure was correlated with the decrease in the GFR observed during the study. In this innovative and complex renal assessment during and after RLT, we found a permanent 10% per year decrease in the GFR and noticeable disturbances in renal tubule function. The diastolic blood pressure also increased. MDPI 2023-04-19 /pmc/articles/PMC10138694/ /pubmed/37108668 http://dx.doi.org/10.3390/ijms24087508 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Saracyn, Marek
Durma, Adam Daniel
Bober, Barbara
Lubas, Arkadiusz
Kołodziej, Maciej
Kapusta, Waldemar
Dmochowska, Beata
Kamiński, Grzegorz
Renal Disturbances during and after Radioligand Therapy of Neuroendocrine Tumors—Extended Analysis of Potential Acute and Chronic Complications
title Renal Disturbances during and after Radioligand Therapy of Neuroendocrine Tumors—Extended Analysis of Potential Acute and Chronic Complications
title_full Renal Disturbances during and after Radioligand Therapy of Neuroendocrine Tumors—Extended Analysis of Potential Acute and Chronic Complications
title_fullStr Renal Disturbances during and after Radioligand Therapy of Neuroendocrine Tumors—Extended Analysis of Potential Acute and Chronic Complications
title_full_unstemmed Renal Disturbances during and after Radioligand Therapy of Neuroendocrine Tumors—Extended Analysis of Potential Acute and Chronic Complications
title_short Renal Disturbances during and after Radioligand Therapy of Neuroendocrine Tumors—Extended Analysis of Potential Acute and Chronic Complications
title_sort renal disturbances during and after radioligand therapy of neuroendocrine tumors—extended analysis of potential acute and chronic complications
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138694/
https://www.ncbi.nlm.nih.gov/pubmed/37108668
http://dx.doi.org/10.3390/ijms24087508
work_keys_str_mv AT saracynmarek renaldisturbancesduringandafterradioligandtherapyofneuroendocrinetumorsextendedanalysisofpotentialacuteandchroniccomplications
AT durmaadamdaniel renaldisturbancesduringandafterradioligandtherapyofneuroendocrinetumorsextendedanalysisofpotentialacuteandchroniccomplications
AT boberbarbara renaldisturbancesduringandafterradioligandtherapyofneuroendocrinetumorsextendedanalysisofpotentialacuteandchroniccomplications
AT lubasarkadiusz renaldisturbancesduringandafterradioligandtherapyofneuroendocrinetumorsextendedanalysisofpotentialacuteandchroniccomplications
AT kołodziejmaciej renaldisturbancesduringandafterradioligandtherapyofneuroendocrinetumorsextendedanalysisofpotentialacuteandchroniccomplications
AT kapustawaldemar renaldisturbancesduringandafterradioligandtherapyofneuroendocrinetumorsextendedanalysisofpotentialacuteandchroniccomplications
AT dmochowskabeata renaldisturbancesduringandafterradioligandtherapyofneuroendocrinetumorsextendedanalysisofpotentialacuteandchroniccomplications
AT kaminskigrzegorz renaldisturbancesduringandafterradioligandtherapyofneuroendocrinetumorsextendedanalysisofpotentialacuteandchroniccomplications